FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting. This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone.
Inclusion Criteria:
Inclusion Criteria:
- Adult female or male patient (≥18 years old)
- Diagnosis of CKD associated with T2D based on assessment by physician.
- Treatment according to local marketing authorization, finerenone 20 or 10 mg.Treatment should have been started up to 8 weeks before or after the ICF is signed.
- Decision to initiate treatment with finerenone must be made before ICF is signed.
- Signed informed consent